靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期1985-03-18 |
/ Not yet recruiting临床4期IIT 24-hour efficacy and tolerability of the tafluprost-timolol fixed association without preservatives in glaucomatous or ocular hypertensive patients already treated with latanoprost preserved with BAK. A Prospective, open study of 3 months duration. - HERO
Treatment of macular edema secondary to central or branch vein occlusion by dexamethazone intravitreal injection - Ozurdex in post-occlusive macular edema
Comparison of Incidence and Severity of conjunctival hyperemia associated with use of topical Bimatoprost 0.01% and latanoprost 0.005% in Glaucoma or Ocular Hypertensive patients - ND
100 项与 Irccs Fondazione G.B. Bietti Per Lo Studio e La Ricerca 相关的临床结果
0 项与 Irccs Fondazione G.B. Bietti Per Lo Studio e La Ricerca 相关的专利(医药)
100 项与 Irccs Fondazione G.B. Bietti Per Lo Studio e La Ricerca 相关的药物交易
100 项与 Irccs Fondazione G.B. Bietti Per Lo Studio e La Ricerca 相关的转化医学